Last A$0.01 AUD
Change Today 0.00 / 0.00%
Volume 5.4M
As of 11:44 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

imugene ltd (IMU) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - A$0.02
52 Week Low
05/22/14 - A$0.0080
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMUGENE LTD (IMU)

Related News

No related news articles were found.

imugene ltd (IMU) Related Businessweek News

No Related Businessweek News Found

imugene ltd (IMU) Details

Imugene Limited, an immuno-oncology biopharmaceutical company, together with its subsidiaries, engages in the research and development of novel antisense pharmaceuticals in Australia. Its lead product is HER-Vaxx, a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours, including gastric, breast, ovarian, lung, and pancreatic cancers. HER-Vaxx has completed a Phase I study in breast cancer and focuses on a Phase Ib/II study in gastric cancer. The company also has a research programme focused on antigen mimotopes for use in cancer vaccines. Imugene Limited is based in Armadale, Australia.

imugene ltd (IMU) Top Compensated Officers

Chief Financial Officer and Joint Company Sec...
Total Annual Compensation: A$124.8K
Head of Manufacturing & Operations, Member of...
Total Annual Compensation: A$164.8K
Joint Company Secretary
Total Annual Compensation: A$12.0K
Compensation as of Fiscal Year 2014.

imugene ltd (IMU) Key Developments

Imugene Ltd., Annual General Meeting, Nov 25, 2014

Imugene Ltd., Annual General Meeting, Nov 25, 2014.

Imugene Ltd. Announces Resignation of Nicholas Ede as a Director

The board of Imugene Ltd. announced the resignation of Dr. Nicholas Ede as a director of the company. Dr. Ede will continue to be employed by the company as its head of manufacturing and operations. Dr. Ede will assume key operational responsibilities including the management of Her-Vaxx, oversight of preclinical HER-Vaxx development as well as a range of other day to day operational responsibilities.

Imugene Ltd. Presents at 5th Annual Australian Microcap Investment Conference, Oct-21-2014 02:45 PM

Imugene Ltd. Presents at 5th Annual Australian Microcap Investment Conference, Oct-21-2014 02:45 PM. Venue: Sofitel Molbourne On collins, Arthur Streeton Auditorium, 25 Collins Street, Melbourne, VIC 3000, Australia. Speakers: Charles S. Walker, Chief Executive Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMU:AU A$0.01 AUD 0.00

IMU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMU.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.9x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMUGENE LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at